Skip to main content

Breast Cancer Research and Treatment

Ausgabe 3/2017

Inhalt (24 Artikel)

Review

Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review

B. Cabarrou, L. Mourey, F. Dalenc, L. Balardy, D. Kanoun, H. Roché, J. M. Boher, M. E. Rougé-Bugat, Thomas Filleron

Review

Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer

Kathryn J. Ruddy, Holly K. Van Houten, Lindsey R. Sangaralingham, Rachel A. Freedman, Carrie A. Thompson, Shahrukh K. Hashmi, Ahmedin Jemal, Tufia C. Haddad, Sarah Mougalian, Jeph Herrin, Cary Gross, Nilay Shah

Review

Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses

Virginie Nerich, Sopany Saing, Eva-Maria Gamper, Bernhard Holzner, Xavier Pivot, Rosalie Viney, Georg Kemmler

Open Access Review

Risk of death from cardiovascular disease following breast cancer: a systematic review

S. A. M. Gernaat, P. J. Ho, N. Rijnberg, M. J. Emaus, L. M. Baak, M. Hartman, D. E. Grobbee, H. M. Verkooijen

Preclinical study

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)

Diep Ho, Jessica Huang, Judith-Anne W. Chapman, Kim Leitzel, Suhail M. Ali, Lois Shepherd, Wendy R. Parulekar, Catherine E. Ellis, Rocco J. Crescnzo, Liting Zhu, Shakeel Virk, Dora Nomikos, Samuel Aparicio, Karen A. Gelmon, Walter P. Carney, Allan Lipton

Open Access Preclinical study

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis

Gail D. Lewis Phillips, Merry C. Nishimura, Jennifer Arca Lacap, Samir Kharbanda, Elaine Mai, Janet Tien, Kimberly Malesky, Simon P. Williams, Jan Marik, Heidi S. Phillips

Preclinical study

Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer

Madhura G. Kelkar, Bhushan Thakur, Abhishek Derle, Sushmita Chatterjee, Pritha Ray, Abhijit De

Clinical trial

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer

Kara N. Maxwell, Danielle Soucier-Ernst, Emin Tahirovic, Andrea B. Troxel, Candace Clark, Michael Feldman, Christopher Colameco, Bijal Kakrecha, Melissa Langer, David Lieberman, Jennifer J. D. Morrissette, Matt R. Paul, Tien-chi Pan, Stephanie Yee, Natalie Shih, Erica Carpenter, Lewis A. Chodosh, Angela DeMichele

Erratum

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer

Kara N. Maxwell, Danielle Soucier-Ernst, Emin Tahirovic, Andrea B. Troxel, Candace Clark, Michael Feldman, Christopher Colameco, Bijal Kakrecha, Melissa Langer, David Lieberman, Jennifer J. D. Morrissette, Matt R. Paul, Tien-chi Pan, Stephanie Yee, Natalie Shih, Erica Carpenter, Lewis A. Chodosh, Angela DeMichele

Clinical trial

Radiation and depression associated with complications of tissue expander reconstruction

Paul J. Chuba, William A. Stefani, Carrie Dul, Susan Szpunar, Jeffrey Falk, Rachael Wagner, Elango Edhayan, Anna Rabbani, Cynthia H. Browne, Amr Aref

Clinical Trial

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Denise A. Yardley, Edward R. Arrowsmith, Brooke R. Daniel, Janice Eakle, Adam Brufsky, David R. Drosick, Fred Kudrik, Linda D. Bosserman, Mark R. Keaton, Sharon A. Goble, Jeffrey A. Bubis, Victor M. Priego, Kelly Pendergrass, Yvonne Manalo, Martin Bury, Donald S. Gravenor, Gladys I. Rodriguez, Roger C. Inhorn, Robyn R. Young, William N. Harwin, Caryn Silver, John D. Hainsworth, Howard A. Burris III

Clinical trial

Effect of age on breast cancer screening using tomosynthesis in combination with digital mammography

Elizabeth A. Rafferty, Stephen L. Rose, Dave P. Miller, Melissa A. Durand, Emily F. Conant, Debra S. Copit, Sarah M. Friedewald, Donna M. Plecha, Ingrid L. Ott, Mary K. Hayes, Kara L. Carlson, Thomas M. Cink, Lora D. Barke, Linda N. Greer, Loren T. Niklason

Open Access Clinical trial

High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers

Cecilia Ahlin, Claudia Lundgren, Elin Embretsén-Varro, Karin Jirström, Carl Blomqvist, M. -L. Fjällskog

Epidemiology

Childhood and teenage physical activity and breast cancer risk

Nicole M. Niehoff, Alexandra J. White, Dale P. Sandler

Epidemiology

Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction

Molly Scannell Bryan, Maria Argos, Irene L. Andrulis, John L. Hopper, Jenny Chang-Claude, Kathleen Malone, Esther M. John, Marilie D. Gammon, Mary Daly, Mary Beth Terry, Saundra S. Buys, Dezheng Huo, Olofunmilayo Olopade, Jeanine M. Genkinger, Farzana Jasmine, Muhammad G. Kibriya, Lin Chen, Habibul Ahsan

Epidemiology

Nationwide cross-sectional adherence to mammography screening guidelines: national behavioral risk factor surveillance system survey results

Anand Narayan, Alexander Fischer, Zihe Zhang, Ryan Woods, Elizabeth Morris, Susan Harvey

Brief Report

Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients

Andy Göbel, Jan D. Kuhlmann, Theresa Link, Pauline Wimberger, Andrew J. Browne, Martina Rauner, Lorenz C. Hofbauer, Tilman D. Rachner

Erratum

Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications

Jessica A. Cintolo-Gonzalez, Danielle Braun, Amanda L. Blackford, Emanuele Mazzola, Ahmet Acar, Jennifer K. Plichta, Molly Griffin, Kevin S. Hughes

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.